The Full Wiki

Sanofi-Aventis: Wikis

  
  
  

Note: Many of our articles have direct quotes from sources you can cite, within the Wikipedia article! This article doesn't yet, but we're working on it! See more info or our list of citable articles.

Encyclopedia

From Wikipedia, the free encyclopedia

Sanofi-Aventis S.A.
Type Public (Euronext: SAN, NYSESNY, LSE: 0I42, FWB: SNW)
Founded 20 August 2004 (by acquisition)
Headquarters Paris, France
Key people Chris Viehbacher (CEO), Jean-François Dehecq (Chairman of the board)
Industry Pharmaceuticals
Products Prescription and over-the-counter drugs for thrombosis, cardiovascular disease, diabetes, central nervous system disorders, oncology and internal medicine, vaccines (list...)
Revenue 27.57 billion (2008)[1]
Operating income €4.394 billion (2008)[1]
Profit €3.851 billion (2008)[1]
Employees 98,210 (2008)[1]
Subsidiaries Sanofi Pasteur
Website en.sanofi-aventis.com

Sanofi-Aventis (Euronext: SAN, NYSESNY), headquartered in Paris, France, is a multinational pharmaceutical company, the world's fourth-largest by prescription sales.[2][3] Sanofi-Aventis engages in the research and development, manufacturing and marketing of pharmaceutical products for sale principally in the prescription market, but the firm also develops over-the-counter medication. Sanofi-Aventis covers 7 major therapeutic areas: cardiovascular, central nervous system, diabetes, internal medicine, oncology, thrombosis and vaccines (it is the world's largest producer of the latter through its subsidiary Sanofi Pasteur).[4] The company is a full member of the European Federation of Pharmaceutical Industries and Associations (EFPIA).[5]

Contents

History

Sanofi-Aventis

Sanofi-Aventis was formed in 2004 when Sanofi-Synthélabo acquired Aventis. In early 2004, Sanofi-Synthélabo made a hostile takeover bid worth €47.8 bn for Aventis. Initially, Aventis rejected the bid because it felt that the bid offered inferior value based on the company's share value. The three-month takeover battle concluded when Sanofi-Synthélabo launched a friendly bid of €54.5 bn in place of the previously rejected hostile bid. French government intervention also played an active role. The French government, desiring what they called a "local solution", put heavy pressure on Sanofi-Synthélabo to raise its bid for Aventis after it became known that Novartis, a Swiss pharmaceutical company, was in the running.

Sanofi-Synthélabo

Sanofi-Synthélabo was formed in 1999 when Sanofi (former subsidiary of Total) merged with Synthélabo (former subsidiary of L'Oréal). The merged company was based in Paris, France.

Aventis

Aventis was formed in 1999 when French company Rhône-Poulenc S.A. merged with the German corporation Hoechst Marion Roussel, which itself was formed from the 1995 merger of Hoechst AG with Roussel Uclaf and Marion Merrell Dow. The merged company was based in Schiltigheim, near Strasbourg, France.

Business

Products

Pharmaceuticals produced by Sanofi-Aventis include Lovenox/Clexane for thrombosis (its biggest seller in 2008),[6] Plavix/Iscover for atherothrombosis, Apidra and Lantus for diabetes, Taxotere for breast, lung and prostate cancer, Eloxatin for colorectal cancer, Stilnox/Ambien/Ambien CR/Myslee/Zolfresh/Zolt/Stilnoct for insomnia, Copaxone for multiple sclerosis, Aprovel/Avapro/Karvea and Delix/Tritace/Triatec for hypertension, Allegra/Telfast and Nasacort for allergic rhinitis, Menactra for meningitis, Xatral for benign prostatic hyperplasia, Actonel for osteoporosis and Paget’s disease and Depakine and Depakote for epilepsy.

Management

Dehecq was the General Manager of Sanofi from its creation in 1973 until 2007.

Stockholders

As of 31 January 2009:[1]

  • Breakdown of share ownership: 11.09% by Total, 8.99% by L'Oréal, 0.76% treasury shares and 1.30% employees. The remaining 77.86% are publicly traded.
  • Voting rights distribution: 18.11% to Total, 14.89% to L'Oréal, 1.96% to employees, and 65.04% to the public.

Collaborative research

In addition to internal research and development activities Sanofi-Aventis is also involved in publicly funded collaborative research projects, with other industrial and academic partners. One example in the area of non-clinical safety assessment is the InnoMed PredTox.[9][10] The company is expanding its activities in joint research projects within the framework of the Innovative Medicines Initiative of EFPIA and the European Commission.[11]

Aventis Foundation

The Aventis Foundation [12], a German charitable trust, was established in 1996 as the Hoechst Foundation with an endowment of €50 million. In 2000, the foundation was renamed the Aventis Foundation. Its aim is to promote music, theater, art, literature, higher education and healthcare research.

See also

References

  1. ^ a b c d e "Annual Report 2008". Sanofi-Aventis. http://en.sanofi-aventis.com/binaries/20F_2008_tcm28-24281.pdf. Retrieved 2009-04-19. 
  2. ^ IMS Health 2008
  3. ^ Keller, Greg (10 September 2008). "Sanofi names Viehbacher as new CEO". Associated Press (USA Today). http://www.usatoday.com/money/economy/2008-09-10-4035378426_x.htm. Retrieved 2009-04-19. 
  4. ^ "Sanofi-Aventis to sign deal to build flu vaccine plant in China - source". AFX News (Forbes). 23 November 2007. http://www.forbes.com/feeds/afx/2007/11/23/afx4368351.html. Retrieved 2009-04-19. 
  5. ^ "The Pharmaceutical Industry in Figures - 2008 Edition". European Federation of Pharmaceutical Industries and Associations (EFPIA). pp. 49. http://www.efpia.eu/content/default.asp?PageID=559&DocID=4883. Retrieved 2008-08-25. 
  6. ^ "Annual Review 2008". Sanofi-Aventis. http://en.sanofi-aventis.com/binaries/Sanofi_RA_EN_tcm28-24842.pdf. Retrieved 2009-04-19. 
  7. ^ Sanofi-Aventis splits chairman-CEO job; Dehecq stays chairman, Le Fur named CEO 15.12.2006
  8. ^ Chris Viehbacher wird Nachfolger von Sanofi-Aventis-Chef Le Fur 10.09.2008
  9. ^ Mattes WB (2008), Public consortium efforts in toxicogenomics, Methods Mol Biol. 2008;460:221-38 [1]
  10. ^ "InnoMed PredTox Member Organizations". http://www.innomed-predtox.com/consortium/members/. Retrieved 2008-08-25. 
  11. ^ Innovative Medicines Initiative. "IMI Call Topics 2008". IMI-GB-018v2-24042008-CallTopics.pdf. European Commission. http://imi.europa.eu/docs/calls01_en.zip. Retrieved 2008-08-25. 
  12. ^ http://www.aventis-foundation.org/

External links


Sanofi-Aventis S.A.
Type Société Anonyme (Euronext: SAN, NYSESNY, LSE: 0I42, FWB: SNW)
Industry Pharmaceuticals
Founded 20 August 2004 (by acquisition)
Headquarters 13th arrondissement, Paris, France
Key people Chris Viehbacher (CEO), Jean-François Dehecq (Chairman of the board)
Products Prescription and over-the-counter drugs for thrombosis, cardiovascular disease, diabetes, central nervous system disorders, oncology and internal medicine, vaccines (list...)
Revenue 29.31 billion (2009)[1]
Operating income €6.366 billion (2009)[1]
Profit €5.265 billion (2009)[1]
Employees 104,870 (2009)[1]
Subsidiaries Sanofi Pasteur
Website sanofi-aventis.com

Sanofi-Aventis (Euronext: SAN, NYSESNY), headquartered in Paris, France, is a multinational pharmaceutical company, the world's fourth-largest by prescription sales.[2][3] Sanofi-Aventis engages in the research and development, manufacturing and marketing of pharmaceutical products for sale principally in the prescription market, but the firm also develops over-the-counter medication. Sanofi-Aventis covers 7 major therapeutic areas: cardiovascular, central nervous system, diabetes, internal medicine, oncology, thrombosis and vaccines (it is the world's largest producer of the latter through its subsidiary Sanofi Pasteur).[4] The company is a full member of the European Federation of Pharmaceutical Industries and Associations (EFPIA).[5]

Contents

History

Sanofi-Aventis

Sanofi-Aventis was formed in 2004 when Sanofi-Synthélabo acquired Aventis. In early 2004, Sanofi-Synthélabo made a hostile takeover bid worth €47.8 bn for Aventis. Initially, Aventis rejected the bid because it felt that the bid offered inferior value based on the company's share value. The three-month takeover battle concluded when Sanofi-Synthélabo launched a friendly bid of €54.5 bn in place of the previously rejected hostile bid. French government intervention also played an active role. The French government, desiring what they called a "local solution", put heavy pressure on Sanofi-Synthélabo to raise its bid for Aventis after it became known that Novartis, a Swiss pharmaceutical company, was in the running.

October 2010: Sanofi-Aventis SA will lay off 1,700 US employees due to restructuring triggered by growing generic competition and other factors. The cuts being completed throughout 2011 according to transition needs. The layoffs amount to about 25 percents of the workers in the company's US pharmaceutical business. The company deny the action is related with aquisition plan of buying US biotech firm Genzyme Corp.[6]

Sanofi-Synthélabo

Sanofi-Synthélabo was formed in 1999 when Sanofi (former subsidiary of Total) merged with Synthélabo (former subsidiary of L'Oréal). The merged company was based in Paris, France.

Aventis

Aventis was formed in 1999 when French company Rhône-Poulenc S.A. merged with the German corporation Hoechst Marion Roussel, which itself was formed from the 1995 merger of Hoechst AG with Roussel Uclaf and Marion Merrell Dow. The merged company was based in Schiltigheim, near Strasbourg, France.

Business

Products

Pharmaceuticals produced by Sanofi-Aventis include Lovenox/Clexane for thrombosis (its biggest seller in 2008),[7] Plavix/Iscover for atherothrombosis, Apidra and Lantus for diabetes, Taxotere for breast, lung and prostate cancer, Eloxatin for colorectal cancer, Stilnox/Ambien/Ambien CR/Myslee/Zolfresh/Zolt/Stilnoct for insomnia, Copaxone for multiple sclerosis, Aprovel/Avapro/Karvea and Delix/Tritace/Triatec for hypertension, Allegra/Telfast and Nasacort for allergic rhinitis, Menactra for meningitis, Xatral for benign prostatic hyperplasia, Actonel for osteoporosis and Paget’s disease and Depakine and Depakote for epilepsy, Biprofened for pain.

Management

Dehecq was the General Manager of Sanofi from its creation in 1973 until 2007.

Stockholders

As of 31 January 2010:[1]

  • Breakdown of share ownership: 6.96% by Total, 8.97% by L'Oréal, 0.71% treasury shares and 1.37% employees. The remaining 77.86% are publicly traded.
  • Voting rights distribution: 11.76% to Total, 15.36% to L'Oréal, 2.10% to employees, and 70.78% to the public.

Head office

[[File:|thumb|Head office in Paris]] The head office is located in the 13th arrondissement of Paris, 174 Avenue de France. The architecture of the head office is of the predominate style of the area surrounding the François Mitterrand Library. After Sanofi and Aventis merged, the employees at the former Aventis head office in Schiltigheim, Alsace moved to Paris.[10]

Collaborative research

In addition to internal research and development activities Sanofi-Aventis is also involved in publicly funded collaborative research projects, with other industrial and academic partners. One example in the area of non-clinical safety assessment is the InnoMed PredTox.[11][12] The company is expanding its activities in joint research projects within the framework of the Innovative Medicines Initiative of EFPIA and the European Commission.[13]

In June 2010, Sanofi-aventis and the Charite University of Berlin signed a cooperation agreement for the research and development of medicines and therapies.[14]

Aventis Foundation

The Aventis Foundation [15], a German charitable trust, was established in 1996 as the Hoechst Foundation with an endowment of €50 million. In 2000, the foundation was renamed the Aventis Foundation. Its aim is to promote music, theater, art, literature, higher education and healthcare research.

See also

File:Arc Triomphe.jpg Paris portal
Companies portal

References

  1. ^ a b c d e "Annual Report 2009". Sanofi-Aventis. http://en.sanofi-aventis.com/binaries/20F_2009_tcm28-27683.pdf. Retrieved 2010-03-21. 
  2. ^ IMS Health 2008
  3. ^ Keller, Greg (10 September 2008). "Sanofi names Viehbacher as new CEO". Associated Press (USA Today). http://www.usatoday.com/money/economy/2008-09-10-4035378426_x.htm. Retrieved 2009-04-19. 
  4. ^ "Sanofi-Aventis to sign deal to build flu vaccine plant in China - source". AFX News (Forbes). 23 November 2007. http://www.forbes.com/feeds/afx/2007/11/23/afx4368351.html. Retrieved 2009-04-19. 
  5. ^ "The Pharmaceutical Industry in Figures - 2008 Edition". European Federation of Pharmaceutical Industries and Associations (EFPIA). pp. 49. http://www.efpia.eu/content/default.asp?PageID=559&DocID=4883. Retrieved 2008-08-25. 
  6. ^ Sanofi-Aventis To Lay Off 1,700 US Employees http://www.cbsnews.com/stories/2010/10/08/ap/health/main6939445.shtml
  7. ^ "Annual Review 2008". Sanofi-Aventis. http://en.sanofi-aventis.com/binaries/Sanofi_RA_EN_tcm28-24842.pdf. Retrieved 2009-04-19. 
  8. ^ Sanofi-Aventis splits chairman-CEO job; Dehecq stays chairman, Le Fur named CEO 15.12.2006
  9. ^ Chris Viehbacher wird Nachfolger von Sanofi-Aventis-Chef Le Fur 10.09.2008
  10. ^ "Sanofi-Aventis : regroupement à Paris." Le Journal du Net. Retrieved on 28 September 2010.
  11. ^ Mattes WB (2008), Public consortium efforts in toxicogenomics, Methods Mol Biol. 2008;460:221-38 [1]
  12. ^ "InnoMed PredTox Member Organizations". http://www.innomed-predtox.com/consortium/members/. Retrieved 2008-08-25. 
  13. ^ Innovative Medicines Initiative. "IMI Call Topics 2008". IMI-GB-018v2-24042008-CallTopics.pdf. European Commission. http://imi.europa.eu/docs/calls01_en.zip. Retrieved 2008-08-25. 
  14. ^ Sanofi-aventis, Charite University Sign Cooperation Agreement News article from InfoGrok.
  15. ^ http://www.aventis-foundation.org/

External links








Got something to say? Make a comment.
Your name
Your email address
Message